Literature DB >> 19097556

RSV disease in the pediatric population: epidemiology, seasonal variability, and long-term outcomes.

Eric A F Simões1.   

Abstract

Infants younger than 1 year, and especially premature infants, are susceptible to severe RSV disease, which accounts for up to 126,000 hospitalizations each year. In the United States, the RSV season generally extends from November though March, but varies considerably both temporally and geographically. Studies, such as the one we have conducted in Colorado, indicate that the RSV season can even vary among local communities. In addition to seasonal variability, other independent risk factors also have to be taken into consideration when considering RSV immunoprophylaxis. Among these are a GA of less than 33 weeks, infants with CLD or CHD or who are immunosuppressed, male sex, household crowding, and daycare attendance. Exposure to indoor tobacco smoke and abbreviated breast feeding (less than 2 months) also may be pertinent risk factors. The Colorado studies show that high altitude also increases the risk of RSV hospitalization. Although hospitalization is a major outcome of severe RSV infections in infants, the development of wheezing and physician-diagnosed asthma later in life may be a long-term outcome that should be considered.

Entities:  

Mesh:

Year:  2008        PMID: 19097556

Source DB:  PubMed          Journal:  Manag Care        ISSN: 1062-3388


  9 in total

1.  Exogenous administration of vascular endothelial growth factor prior to human respiratory syncytial virus a2 infection reduces pulmonary pathology in neonatal lambs and alters epithelial innate immune responses.

Authors:  Alicia K Olivier; Jack M Gallup; Albert van Geelen; Mark R Ackermann
Journal:  Exp Lung Res       Date:  2011-02-11       Impact factor: 2.459

2.  Respiratory syncytial virus nonstructural proteins decrease levels of multiple members of the cellular interferon pathways.

Authors:  Samer Swedan; Alla Musiyenko; Sailen Barik
Journal:  J Virol       Date:  2009-07-22       Impact factor: 5.103

Review 3.  Glucocorticoids for acute viral bronchiolitis in infants and young children.

Authors:  Ricardo M Fernandes; Liza M Bialy; Ben Vandermeer; Lisa Tjosvold; Amy C Plint; Hema Patel; David W Johnson; Terry P Klassen; Lisa Hartling
Journal:  Cochrane Database Syst Rev       Date:  2013-06-04

Review 4.  Respiratory syncytial virus infection: mechanisms of redox control and novel therapeutic opportunities.

Authors:  Roberto P Garofalo; Deepthi Kolli; Antonella Casola
Journal:  Antioxid Redox Signal       Date:  2012-09-07       Impact factor: 8.401

5.  Characterizing the risk of respiratory syncytial virus in infants with older siblings: a population-based birth cohort study.

Authors:  P Jacoby; K Glass; H C Moore
Journal:  Epidemiol Infect       Date:  2016-11-08       Impact factor: 4.434

6.  Nanoparticles increase human bronchial epithelial cell susceptibility to respiratory syncytial virus infection via nerve growth factor-induced autophagy.

Authors:  Sreeparna Chakraborty; Vincent Castranova; Miriam K Perez; Giovanni Piedimonte
Journal:  Physiol Rep       Date:  2017-07-11

Review 7.  Respiratory virus modulation of host nucleocytoplasmic transport; target for therapeutic intervention?

Authors:  Leon Caly; Reena Ghildyal; David A Jans
Journal:  Front Microbiol       Date:  2015-08-14       Impact factor: 5.640

8.  Reducing Antibiotic Use in Respiratory Syncytial Virus-A Quality Improvement Approach to Antimicrobial Stewardship.

Authors:  Maria Lyn Quintos-Alagheband; Estela Noyola; Sejal Makvana; Gladys El-Chaar; Shan Wang; Rose Calixte; Leonard R Krilov
Journal:  Pediatr Qual Saf       Date:  2017-12-01

9.  Natural history and epidemiology of respiratory syncytial virus infection in the Middle East: Hospital surveillance for children under age two in Jordan.

Authors:  Natasha Halasa; John Williams; Samir Faouri; Asem Shehabi; Sten H Vermund; Li Wang; Christopher Fonnesbeck; Najwa Khuri-Bulos
Journal:  Vaccine       Date:  2015-08-24       Impact factor: 4.169

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.